Use of direct-antiviral agents helps overcome hepatitis C recurrence in liver transplant patients
New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation ...
Apr 25, 2015
0
7